EVE Health Group (ASX: EVE) Announces National Telehealth Partnership with hubMed
EVE Health Group Limited (ASX: EVE) has announced a Patient Support Telehealth Services Agreement with hubMed Pty Ltd in a recent investor update. This agreement establishes a nationwide programme to enhance care for patients prescribed EVE’s therapeutic products in women’s and men’s health. The EVE Health hubMed Partnership is a strategic move to strengthen continuity of care and patient confidence, particularly for conditions that are often under-diagnosed.
This collaboration follows the recent launch of Dyspro™ for dysmenorrhoea and supports the upcoming launch of Libbo™ for erectile dysfunction. By expanding EVE’s telehealth network, the agreement enhances the company’s commercialisation infrastructure at a key growth phase. Such patient support programmes are recognised as important competitive differentiators in pharmaceutical markets.
Well-executed patient support can potentially improve treatment adherence and real-world outcomes. These factors directly influence product uptake and long-term revenue sustainability. Furthermore, this flexible arrangement addresses gaps in continuity of care whilst minimising financial risk through a scalable payment model aligned with prescription volumes.
What is the Structure of the EVE Health hubMed Partnership?
The EVE Health hubMed Partnership has an initial 12-month term and continues on a rolling 12-month basis unless terminated. The agreement is non-exclusive and does not impose any long-term commitment or minimum activity levels, providing both companies with significant operational flexibility.
EVE pays a monthly service fee to hubMed based on the number of patient support interactions delivered. Importantly for the company’s financials, there are no upfront fees, fixed charges, or minimum interaction volumes required under this arrangement.
This flexible cost structure aligns expenses directly with product adoption, which minimises financial risk during the crucial commercialisation phase. The payment model allows EVE to scale its support services in line with prescription volumes rather than committing to fixed overheads that could strain resources.
| Agreement Component | Details |
|---|---|
| Initial Term | 12 months |
| Renewal Structure | Rolling 12-month periods |
| Commitment Level | Non-exclusive, no minimums |
| Payment Model | Monthly fee based on actual patient interactions |
| Upfront Costs | None |
How Does the Patient Support Programme Address Adherence Challenges?
The new programme provides structured follow-up through Registered Nurses who reinforce safe product use, triage patient concerns, and communicate with treating practitioners when clinically necessary. This model creates regular touchpoints designed to support treatment adherence—a critical success factor for pharmaceutical products.
Improved patient adherence directly impacts revenue potential and competitive positioning. In addition, the programme complements traditional medical channels rather than replacing them, creating a layered support system that enhances overall care quality.
Registered Nurses can address early symptom concerns, reinforce clinical guidance, and facilitate timely communication between patients and their prescribers. This approach helps ensure patients remain informed and confident throughout their treatment journey.
“Women’s and men’s health conditions are often overlooked, and patients benefit greatly from reliable follow up and trusted clinical support. This partnership strengthens our ability to provide that support… It is an important step in delivering better outcomes for patients who are prescribed our therapies,” said Damian Wood, Chief Executive Officer of EVE Health Group.
What Makes hubMed a Suitable Partner for EVE Health?
hubMed is an Australian telehealth provider focused on making healthcare more convenient and patient-centred. The company connects individuals with telehealth services that support a wide range of health priorities, aligning seamlessly with EVE’s objectives for patient support and continuity of care.
The collaboration benefits from hubMed’s established clinical governance framework and its team of Registered Nurses. This expertise is particularly valuable in women’s and men’s health, where conditions often face stigma and delayed help-seeking.
“Our Registered Nurses have significant experience supporting patients in areas where continuity of care is especially important. We are pleased to partner with EVE on a programme that prioritises patient wellbeing, safety and communication with prescribers,” said Jessica Stewart, Managing Director of hubMed.
Product-Specific Support Under the Partnership
The agreement provides tailored support frameworks for EVE’s two lead products, Dyspro™ and Libbo™, each addressing unique barriers to treatment adherence.
How Does the Programme Support Dyspro Patients?
For patients prescribed Dyspro (dysmenorrhoea), the programme delivers scheduled Registered Nurse follow-up to help ensure adherence and reinforce correct use. Dysmenorrhoea requires ongoing treatment, and this structured follow-up helps patients navigate their treatment decisions. A recent Australian study found that 77% of women aged 18 to 44 experience disruptive menstrual symptoms.
What Support Does the Programme Provide for Libbo Users?
For patients prescribed Libbo (erectile dysfunction), the programme provides structured Registered Nurse contact to support correct use and triage non-urgent issues. This confidential telehealth environment encourages open dialogue, tackling the stigma common in men’s sexual health. Erectile dysfunction affects one in five men over the age of 18.
| Product | Therapeutic Area | Support Focus | Key Patient Benefits |
|---|---|---|---|
| Dyspro™ | Dysmenorrhoea | Adherence reinforcement, symptom triage | Improved compliance with chronic pain management |
| Libbo™ | Erectile Dysfunction | Correct use support, stigma reduction | Enhanced treatment confidence in a confidential setting |
Continuity of Care in Pharmaceutical Commercialisation
For investors, continuity of care and patient adherence are critical considerations in a pharmaceutical product’s success. These factors often determine whether products meet commercial expectations, making this EVE Health hubMed Partnership strategically significant.
Adherence rates, which measure how consistently patients follow prescribed treatments, typically range from 50-70% for chronic medications. Poor adherence is a primary reason that pharmaceutical products underperform commercially, as real-world results often differ from those seen in controlled clinical trials.
Patient support programmes that improve adherence can directly impact revenue. Higher adherence rates translate to sustained prescription volumes and better treatment outcomes. Furthermore, real-world evidence (RWE) collected through such programmes provides invaluable data for future product development and regulatory submissions, strengthening a product’s value proposition to clinicians and investors.
Want more ASX news?
Looking to stay ahead of major developments in ASX healthcare companies? Subscribe to StockWire X’s free Big News Blasts and join over 20,000 investors receiving instant email alerts on significant healthcare announcements, each accompanied by detailed analysis. With a quality filter ensuring only major news events are distributed, subscribers gain access to the most important market-moving information without the noise. Join today to receive comprehensive insights delivered directly to your inbox.